Tag:
Sandoz
Latest Headlines
Latest Headlines
Novartis now top dog in skin drugs with $1.5B Fougera buy
Novartis has snapped up Fougera Pharmaceuticals, a U.S.-based maker of generic skin treatments, for $1.5 billion.
Sandoz transferring cGMP expertise to Africa's Cinpharm
Sandoz sees lots of potential but is taking an indirect route to build a production footprint in sub-Saharan Africa.
Novartis remediation drags on longer than expected
In reporting an 8% first-quarter earnings decline to shareholders, Novartis acknowledged the company's inability to meet GMPs at a variety of plants played a big role in that dip.
Sandoz Canada president explains shortages to House of Commons
Drug shortages brought on by difficulties at Sandoz's Boucherville, Quebec, plant have landed the president of the Novartis subsidiary in the hot seat before a committee of the Canadian House of Commons.
Novartis plant disruptions affect pet treatments
Manufacturing problems and disruptions at Novartis ($NVS) plants in Nebraska and Canada led to shortages that have left an ugly trail of unhappy healthcare providers and consumers.
Pfizer returns Xanax to UAE
The drug was in short supply for weeks after a change in where the anti-anxiety drug is manufactured.
Health Canada tells hospitals to quarantine morphine from Sandoz
Sandoz Canada is in the spotlight again this week after Canadian health officials told hospitals to quarantine boxes of the company's injectable morphine after one was found to contain another drug.
Sandoz finds outside suppliers for drugs in shortage
Sandoz officials say the company is making every effort to meet patients needs for the critical medications produced at its Boucherville, Quebec, plant which first slowed production for upgrades to meet FDA concerns and then had a fire that temporarily stopped lines.
Sandoz: We won't hike prices in Canada during shortage
Sandoz is assuring Canadians that it doesn't view the current drug shortage in that country as an opportunity to hike prices on its meds. The Novartis ( $NVS ) unit has been at the center of the shortage, particularly after one of its plants had to reduce production because of GMP issues.
Sandoz's role in Canadian drug shortages adds to calls for regulation
The possibility that Sandoz, the generic arm of Novartis, might benefit from the shortage of drugs caused by problems at its Canadian plant is fueling the debate there over how to handle drug shortages in the country.
